9-ING-41

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].

Product Specifications

CAS Number

[1034895-42-5]

Product Name Alternative

Elraglusib

UNSPSC

12352005

Hazard Statement

H301, H311, H331, H341

Target

Apoptosis; Autophagy; GSK-3

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/9-ing-41.html

Purity

99.13

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=O

Molecular Formula

C22H13FN2O5

Molecular Weight

404.35

Precautions

H301, H311, H331, H341

References & Citations

[1]Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29 (8) :717-724.|[2]Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134 (4) :363-373.|[3]Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl- (indol-3-yl) maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52 (7) :1853-63.|[4]Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9 (1) :19977.